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Esteban Porrini3,7, Marı́a José Soler3,8,9 and Alberto Ortiz1,2,3
1IIS-Fundacion Jimenez Diaz UAM and School of Medicine, UAM, Madrid, Spain, 2REDINREN, Madrid, Spain,
3GEENDIAB, Barcelona, Spain, 4Hospital Clı́nico Universitario, Universitat de Valencia-INCLIVA, Valencia,
Spain, 5Bellvitge University Hospital, Hospitalet, Barcelona, Spain, 6Unidad de Investigación y Servicio de
Nefrologı́a, Hospital Universitario Nuestra Se~nora de Candelaria, Santa Cruz de Tenerife, Spain, 7Instituto de
Tecnologı́as Biomédicas, Hospital Universitario de Canarias, Universidad de La Laguna, Santa Cruz de
Tenerife, Spain, 8Nephrology Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de
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ABSTRACT
In April 2019, two major Phase 3 randomized clinical trials were published that assessed primary renal outcomes in diabetic
kidney disease (DKD) in type 2 diabetes mellitus (T2DM). The Canagliflozin and Renal Events in Diabetes with Established
Nephropathy Clinical Evaluation (CREDENCE) tested an already available antidiabetic drug, canagliflozin, and the Study of
Diabetic Nephropathy with Atrasentan (SONAR) tested a novel molecule, the endothelin-1 receptor blocker atrasentan, both
on top of renin–angiotensin system blockade. Both trials demonstrated significant nephroprotection in patients with overt
DKD (albuminuria >300 mg/g urinary creatinine) for combined primary endpoints of end-stage kidney disease (ESKD),
doubling of serum creatinine or death from renal or cardiovascular causes in CREDENCE {hazard ratio [HR] 0.70 [95%
confidence interval (CI) 0.59–0.82]} and ESKD and doubling of serum creatinine in SONAR [HR 0.65 (95% CI 0.49–0.88)].
Canagliflozin also decreased the secondary renal endpoint ESKD, doubling of serum creatinine or renal death [HR 0.66 (95%
CI 0.53–0.81)], which was similar in nature and impact to the primary endpoint in SONAR. In addition, canagliflozin
decreased a secondary endpoint of cardiovascular death or hospitalization for heart failure [HR 0.69 (95% CI 0.57–0.83)],
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whereas atrasentan had no significant impact on a secondary cardiovascular composite endpoint or on hospital admissions
for heart failure and, despite restrictive exclusion criteria, there was a non-significant trend towards more frequent
episodes of heart failure. Based on these results, canagliflozin will likely be approved for the indication of treating DKD in
T2DM and the estimated glomerular filtration rate threshold for prescribing it will be lifted, whereas the future and place of
atrasentan in the treatment of DKD remain unclear.
Keywords: albuminuria, atrasentan, canagliflozin, chronic kidney disease, diabetic kidney disease, endothelin,
sodium-glucose cotransporter-2 (SGLT2) inhibitor
April 2019 saw the publication of positive results from two ma-
jor Phase 3 randomized clinical trials (RCTs) assessing primary
renal outcomes in diabetic kidney disease (DKD) of type 2 diabe-
tes mellitus (T2DM) patients. The approach was very different:
The Canagliflozin and Renal Events in Diabetes with
Established Nephropathy Clinical Evaluation (CREDENCE) tested
an already available antidiabetic drug, canagliflozin [1] and the
Study of Diabetic Nephropathy with Atrasentan (SONAR) tested
a novel molecule, the endothelin-1 receptor blocker atrasentan
[2]. We now discuss what these results will mean in the near fu-
ture for the practicing nephrologist, as they will likely result in a
dramatic paradigm change in the management of DKD. Thus, in
the past 20 years, only renin–angiotensin system (RAS) blockers
have shown a nephroprotective effect on DKD as a primary end-
point in a placebo-controlled RCT, whereas numerous other tri-
als have failed to demonstrate a benefit [3, 4].
WHAT IS DKD?
A recent consensus conference considered DKD as chronic kid-
ney disease (CKD) attributable to diabetes, where CKD is defined
by an estimated glomerular filtration rate (eGFR) <60 mL/min/
1.73 m2 or a urinary albumin:creatinine ratio (UACR) 30 mg/g
creatinine [5, 6]. Thus DKD is usually a clinical diagnosis not
confirmed by kidney biopsy. Pathological features of DKD may
be present in the absence of and may precede pathological albu-
minuria [7]. The terms DKD and diabetic nephropathy are fre-
quently used interchangeably, although it has been argued that
diabetic nephropathy should be reserved for those patients with
histopathological confirmation of the diagnosis [7]. However, di-
abetic patients may also have non-diabetic causes of CKD, espe-
cially if reduced eGFR coexists with normoalbuminuria and
additional red flags. A diagnosis of DKD implies both an in-
creased risk of end-stage renal disease (ESRD) ultimately requir-
ing renal replacement therapy (RRT) and an increased risk of
premature death, mainly due to cardiovascular disease [8]. The
classical clinical spectrum of DKD consists of the progression
from microalbuminuria (UACR 30–300 mg/g, currently termed
A2 albuminuria) to macroalbuminuria (UACR >300 mg/g, cur-
rently termed A3 albuminuria). While 25–35% of DKD patients
have decreased renal function despite normoalbuminuria
(UACR <30 mg/g, currently termed as A1 albuminuria) or micro-
albuminuria [9], those with A3 albuminuria (overt DKD) are at
the highest risk of progression and premature death and should
be targeted by trials of novel therapeutic approaches on top of
the current state of the art [10, 11].
WHAT IS THE BURDEN OF DKD?
CKD is one of the fastest growing causes of death worldwide. It
is estimated that, at the current pace of growth, it will become
the second most frequent cause of death before the end of the
century in some developed countries [12]. DKD is a key contrib-
utor to mortality from CKD and the most frequent cause of need
for RRT worldwide [13]. According to Global Burden of Disease
data, DKD was the cause of >425 000 deaths in 2017, an increase
of 37% in the last decade, and accounted for 35% of deaths from
CKD worldwide [14]. T2DM was responsible for >80% of these
DKD deaths [14]. This illustrates the insufficient implementa-
tion or the lack of effective therapeutic approaches [15]. A criti-
cal analysis of currently available therapies and recent results
from RCTs suggests that suboptimal efficacy of current
approaches does play a key role in the dismal outcome of DKD
patients.
WHAT IS THE CURRENT TREATMENT FOR
DKD?
Hyperglycaemia is the driving force for the development of dia-
betic complications, and tight glycaemic control prevents the
development of micro- and macrovascular complications [16].
However, once kidney injury has occurred, additional injury
pathways are recruited and optimal kidney care requires the
combination of antidiabetic with nephroprotective medication.
Nephroprotection based on antiproteinuric therapy with RAS
blockers is the current standard of therapy for non-pregnant di-
abetic patients with either hypertension or pathological albu-
minuria [17]. Angiotensin-converting enzyme inhibitors (ACEis)
or angiotensin receptor blockers (ARBs) are indicated for neph-
roprotection. However, their beneficial nephroprotective effect
has only been demonstrated as secondary prevention, and
American Diabetes Association (ADA) guidelines still do not rec-
ommend ACEis or ARBs for primary prevention of CKD in dia-
betic patients with normal blood pressure or UACR <30 mg/g
and normal eGFR [17]. Dual RAS blockade with ACEis, ARBs or
aliskiren is formally contraindicated following RCT-derived con-
cerns about the efficacy and safety of these combinations [18,
19]. Key RAS blockade trials for DKD in T2DM, such as Reduction
of Endpoints in Non-Insulin-Dependent Diabetes Mellitus with
the Angiotensin II Antagonist Losartan (RENAAL; losartan ver-
sus placebo) or the Irbesartan Diabetic Nephropathy Trial
(IDNT; irbesartan versus placebo or amlodipine) enrolled
patients with overt DKD (UACR >300 mg/g) (Figure 1) and ob-
served a risk reduction for doubling of serum creatinine or ESRD
versus placebo (Figure 2A and B), but the residual risk was still
in the range of 6.0–8.0/100 patient-years for individual end-
points and 11/100 patient-years for the combined endpoint of
doubling of serum creatinine or ESRD (Figure 2C) [3, 4]. Thus, de-
spite the current standard of care, the residual risk for CKD pro-
gression is still substantial, in line with the global statistics for
mortality from CKD and DKD. In recent years, several clinical
trials assessing new molecules, such as paricalcitol, aliskiren,
sulodexide and bardoxolone, have failed to demonstrate a reno-
protective effect on DKD [24–27].
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WHAT IS THE CURRENT ANTIDIABETIC DRUG
OF CHOICE FOR PATIENTS WITH DKD?
Regarding the optimal antidiabetic drugs to prevent DKD in dia-
betic patients or to prevent DKD progression once it has devel-
oped, the recommendations are evolving rapidly. As recently as
2015, the European Renal Best Practice recommended metfor-
min in a dose adapted to renal function as a first-line agent in
DKD patients with eGFR <45/mL/min/1.73 m2 [28, 29], despite a
formal European Medicines Agency (EMA) contraindication for
eGFR <30 mL/min/1.73 m2 that extends to <45 mL/min/1.73 m2
for fixed-dose combinations of metformin with sodium–glucose
cotransporter (SGLT) inhibitors (SGLT2is) [30]. The recommen-
dation to use metformin as a first-line agent whenever not con-
traindicated is in line with the Standards of Medical Care in
Diabetes of the ADA 2018, which additionally recommended not
to initiate metformin if eGFR <45 mL/min/1.73 m2 and to stop it
if eGFR <30 mL/min/1.73 m2 and added no further advice for
patients with DKD regarding the choice of antidiabetic agent
[31], as well as with the 2018 Consensus Report by the ADA and
the European Association for the Study of Diabetes (EASD) for
haemoglobin A1c (HbA1c) goals, treatments and lifestyle man-
agement for T2DM patients with and without complications
[32]. However, this report, published at the end of 2018, clearly
differentiated patients with CKD from non-complicated T2DM
patients and recommended metformin as a first-line agent to
lower glucose in patients with T2DM and CKD without contrain-
dications and to consider adding an SGLT2i if HbA1c targets
were not achieved or replacing a second antidiabetic drug for an
SGLT2i if HbA1c was on target. If the SGLT2 is contraindicated,
then a glucagon-like peptide-1 (GLP-1) receptor agonist shown
to reduce CKD progression may be considered. The recommen-
dation is based on secondary outcome results of the cardiovas-
cular outcomes trials EMPA-REG OUTCOME (empagliflozin;
Empagliflozin Cardiovascular Outcome Event Trial in Type 2
Diabetes Mellitus Patients), CANVAS Program (canagliflozin;
CANagliflozin cardioVascular Assessment Study), LEADER (lira-
glutide; Liraglutide Effect and Action in Diabetes: Evaluation of
Cardiovascular Outcome Results) and SUSTAIN 6 (semaglutide;
Trial to Evaluate Cardiovascular and Other Long-term
Outcomes With Semaglutide in Subjects With Type 2 Diabetes)
[17, 20, 32–35]. Thus only SGLT2i and GLP-1 receptor agonist
have shown any nephroprotective effect beyond their glucose-
lowering effect, albeit up to CREDENCE, as secondary endpoints
in populations not necessarily having DKD [36]. The ADA-EASD
document does not provide a GFR threshold for the indication
of SGLT2i, given that it differs for different regions, but acknowl-
edged the existence of such thresholds. Thus they recom-
mended considering SGLT2i to lower glucose when metformin
failed or could not be used or on top of metformin in patients
with a DKD diagnosis based on albuminuria but, essentially,
with preserved renal function, given the explicit caveats on the
use of SGLT2i in patients with low eGFR. Thus, based on the evi-
dence available in 2018, they recommend considering SGLT2i to
lower serum glucose for albuminuric DKD patients with rela-
tively preserved renal function based on the potential nephro-
protective effects, but stopped short of recommending SGLT2i
to treat DKD. A European Renal and Cardiovascular medicine
FIGURE 1: CKD G (GFR) and A (albuminuria) categories of patients enrolled in RCTs for current DKD therapies, cardiovascular SGLT2i trials, CANVAS and SONAR. Data
from references [1, 2, 4, 20–23]. Data presented as mean 6 SD and albuminuria data as median (IQR). The percentage of patients with eGFR <60 mL/min/1.73 m2 was
25.9, 22.7 and 9.11% in EMPA-REG, CANVAS and DECLARE, respectively. For albuminuria >300 mg/g, the percentages were 11, 7.1 and 6.8%, respectively.
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and DIABESITY consensus statement are aligned with the ADA-
EASD consensus report [37]. Despite the recommendations on
oral antidiabetics, insulin is still commonly used in T2DM, espe-
cially as eGFR decreases [38, 39].
WHAT ARE SGLT2IS?
SGLT2is are the newest class of oral agents to treat T2DM. These




FIGURE 2: Efficacy of nephroprotective therapies. (A) Relative risk or HR for primary endpoint (IDNT and RENAAL: doubling of the serum creatinine concentration, ESRD
or death; CANVAS: doubling of the serum creatinine concentration, ESRD or cardiovascular or renal death). SONAR was omitted because the primary endpoint did not
include death. (B) Relative risk or HR for key renal endpoints explored in all the trials. The original IDNT manuscript did not provide the combined doubling of the se-
rum creatinine concentration and ESRD endpoint. (C) Residual risk for key renal endpoints. In IDNT, the residual risk per 100 person-years was estimated from mean
follow-up and percentage of patients with events. Data from references [2–4]. The comparator for RENAAL and IDNT was placebo/absence of RAS blockade, whereas
the comparator for CREDENCE and SONAR was placebo þ RAS blockade.
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reabsorption in the proximal renal tubule, resulting in increased
urinary glucose excretion and lower blood glucose levels [37]. In
cardiovascular safety trials enrolling patients at high cardiovas-
cular risk (Figure 1), the SGLT2is canagliflozin, dapagliflozin and
empagliflozin reduced cardiovascular risk (Figure 3A) and also
incident or worsening nephropathy as secondary or post hoc kid-
ney outcomes [20, 33, 37, 40, 41].
ARE SGLT2IS INDICATED FOR THE TREATMENT
OF DKD?
Not as of April 2019. The EMA lists as indications for SGLT2i the
treatment of adults with T2DM in monotherapy or combination
therapy and (for dapagliflozin) also for type 1 diabetes mellitus
(T1DM) in combination with insulin (Table 1) [42–44]. There is
no mention of specific indications for DKD patients or to treat
DKD. On the contrary, there is a warning for starting these drugs
in DKD patients that fulfil the eGFR criterion for CKD (SGLT2i
not to be initiated when eGFR <60 mL/min/1.73 m2). This warn-
ing is based on the lower antidiabetic effect of the drugs when
renal function is decreased as well as on concerns about volume
depletion. This warning is expected to change soon once the
regulatory authorities examine the results from CREDENCE. In
this regard, scientific society guidelines and consensus docu-
ments have moved faster than regulatory authorities by recom-
mending considering SGLT2i preferentially to treat diabetes in
patients with DKD and will likely continue to advance in this
major paradigm change by making recommendations on their
role in the treatment of DKD, not just of T2DM.
WHAT WAS THE EVIDENCE BASE TO
INDICATE SGLT2I IN PATIENTS WITH DKD
PATIENTS PRIOR TO CREDENCE?
Before CREDENCE, cardiovascular outcomes trials of SGLT2is
used to lower glucose had enrolled patients at a high cardiovas-
cular risk [20, 33, 40]. These included a significant number of
patients with DKD defined as either eGFR 30–60 mL/min/1.73 m2
or UACR >30 mg/g: as an example, in EMPA-REG OUTCOME, 40%
of patients had pathological albuminuria and an additional 20%
had eGFR 30–60 mL/min/1.73 m2 with normoalbuminuria [45].
However, only 11% had baseline albuminuria >300 mg/g. As a
consequence, the mean levels of eGFR and median levels of
UACR for the full SGLT2i cardiovascular cohort were not in the
DKD range (Figure 1). In addition to significantly lower cardio-
vascular events as defined by at least one primary endpoint
A
B
FIGURE 3: Cardiovascular safety of SGLT2i and atrasentan. Data from (A) cardiovascular outcome trials enrolling T2DM patients at high cardiovascular risk (CANVAS
Program, DECLARE-TIMI and EMPA-REG OUTCOME) [20, 33, 40] and (B) trials enrolling patients with DKD (CANVAS and SONAR) [2, 20] are presented. MACE: major car-
diovascular events: cardiovascular death, myocardial infarction or stroke.
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(Figure 3A), trials with empagliflozin, canagliflozin and dapagli-
flozin observed a significantly lower incidence of renal out-
comes defined by secondary endpoints in these mixed DKD and
non-DKD populations [20, 33, 40].
In EMPA-REG OUTCOME, empagliflozin significantly reduced
incident or worsening nephropathy (defined as decreasing renal
function, developing UACR> 300 mg/g, doubling of serum creat-
inine or developing ESRD or death from ESRD) by almost 40%
{hazard ratio [HR] 0.61 [95% confidence interval (CI) 0.53–0.70]}
[33, 41]. In the CANVAS Program, canagliflozin patients devel-
oped less macroalbuminuria than placebo patients and the
composite outcome (40% reduction in eGFR, RRT or renal death)
was less frequent in canagliflozin than in placebo patients [HR
0.60 (95% CI 0.47–0.77)] [20]. The Multicenter Trial to Evaluate
the Effect of Dapagliflozin on the Incidence of Cardiovascular
Events (DECLARE-TIMI) was published later in 2019. Patients
randomized to dapagliflozin had a 47% lower incidence of the
composite renal outcome [decrease of at least 40% in eGFR to
<60 mL/min/1.73 m2, ESRD or death from renal causes: HR 0.53
(95% CI: 0.430.66)] [40]. However, the incidence of ESRD in the
control population was low (e.g. 0.2/100 patient-years) in EMPA-
REG OUTCOME [41].
In EMPA-REG OUTCOME, 7.7% of the patients had an eGFR
<45 mL/min/1.73 m2 and in the CANVAS Program, 5.5%. In both
studies, the cardiovascular and renal benefits were observed in
both patients with normal and reduced eGFR.
Thus hypothesis-generating evidence had been gathered
prior to CREDENCE from secondary endpoints of cardiovascular
outcomes trials that were very suggestive of a drug class neph-
roprotective effect for SGLT2is. Furthermore, the cardiovascular
and renal benefits of SGLT2is appear to extend to DKD patients
with eGFR in the 30–60 mL/min/1.73 m2 range. But this hypothe-
sis had not been formally tested in an RCT with primary renal
outcomes nor in a full cohort of DKD patients, which is the nov-
elty of CREDENCE.
WHAT WAS LEARNED FROM THE CREDENCE
TRIAL TESTING CANAGLIFLOZIN TO TREAT
DKD?
The results of the CREDENCE trial were published in April 2019.
This is the first RCT of any SGLT2i in which the whole study
population had DKD and the primary endpoint was renal, thus
providing solid evidence for a novel therapeutic indication for
canagliflozin to treat DKD. CREDENCE randomized 4401 T2DM
patients with DKD to canagliflozin or placebo and followed
them for a median of 2.62 years in an event-driven trial
(Figure 1) [2]. It was terminated early because of the evidence of
benefit in a pre-specified interim analysis. The key result is a
risk reduction of 30% in the canagliflozin group for the compos-
ite primary renal outcome, and what is more relevant, these
results were obtained in subjects with eGFR 30–90 mL/min/1.73
m2 and UACR 300–5000 mg/g [2]. It should be noted that patients
were enrolled with an eGFR up to 30 mL/min/1.73 m2, thus po-
tentially expanding a putative canagliflozin indication ‘treat-
ment of DKD’ outside the eGFR limits of the current EMA
statement that canagliflozin should not be initiated when eGFR
is <60 mL/min/1.73 m2 for the indication ‘treatment of T2DM’.
In fact, at baseline, eGFR was 30–44 mL/min/1.73 m2 in 31% of
the patients and 45–60 mL/min/1.73 m2 in 29%. Furthermore,
canagliflozin was maintained until patients started RRT. Thus
this trial established the efficacy for kidney protection and the
safety of the use of canagliflozin at any eGFR as long as the pa-
tient is not on RRT.
Canagliflozin decreased the combined primary endpoint
[ESRD, doubling of serum creatinine or death from renal or car-
diovascular cause; HR 0.70 (95% CI 0.59–0.82)] and the secondary
renal endpoint ESRD, doubling of serum creatinine or renal
death [HR 0.66 (95% CI 0.53–0.81)] (Figure 2B). In addition, cana-
gliflozin decreased the secondary endpoint of cardiovascular
death or hospitalization for heart failure [HR 0.69 (95% CI 0.57–
0.83)] (Figure 3B).
Overall, canagliflozin was safe, with both any and serious
adverse events significantly less frequent than for placebo [HR
0.87 (95% CI 0.82–0.93) and HR 0.87 (95% CI 0.79–0.97), respec-
tively]. Some adverse effects that raised concerns in prior cana-
gliflozin trials were not increased in frequency [HR 1.11 (95% CI
0.79–1.56) for amputation and HR 0.98 (95% CI 0.70–1.37) for frac-
ture], whereas the HR for diabetic ketoacidosis was 10, although
the absolute risk was low (11/2200 patients).
A perspective on the combined cardiovascular and renal
effects of canagliflozin in DKD patients is provided by the mea-
gre advances in cardiovascular outcomes provided by the intro-
duction of RAS blockade. In IDNT (irbesartan), a secondary
cardiovascular outcome of cardiovascular death, myocardial in-
farction, heart failure resulting in hospitalization, stroke or
lower limb amputation was not significantly different from pla-
cebo [HR 0.91 (95% CI 0.72–1.14)] [4]. In RENAAL (losartan), there
were no significant differences for a similar secondary cardio-
vascular outcome (cardiovascular death, myocardial infarction
or unstable angina, stroke, first hospitalization for heart failure
or coronary or peripheral revascularization, risk reduction 10%;
P¼ 0.26) [3]. However, irbesartan reduced the incidence of con-
gestive heart failure necessitating hospitalization by 23% and
there was a non-significant trend (P¼ 0.08) for a reduction of
this outcome for losartan.
IS THERE BIOLOGICAL PLAUSIBILITY FOR
CANAGLIFLOZIN BEING NEPHROPROTECTIVE
ONCE EGFR IS <60 mL/MIN/1.73 M2?
The EMA states that SGLT2i should not be initiated at low eGFR
as the degree of glycosuria and antidiabetic efficacy is lower
when less glucose is filtered by glomeruli. However, there are
several solid hypotheses that may explain nephroprotection
even when the antidiabetic effect is mild [37]. Foremost among
these is a single-nephron impact on glomerular hyperfiltration
Table 1. SGLT2i and atrasentan current (15 April 2019) indications
and use in renal disease by the EMA [42–44]
Indications
Canagliflozin, dapagliflozin and empagliflozin: adults with insuffi-
ciently controlled T2DM as an adjunct to diet and exercise, either
as monotherapy when metformin is considered inappropriate due
to intolerance or in addition to other medicinal products for the
treatment of diabetes.
Dapagliflozin: adults with insufficiently controlled T1DM as an ad-
junct to insulin in patients with BMI 27 kg/m2, when insulin
alone does not provide adequate glycaemic control despite opti-
mal insulin therapy.
Atrasentan: no indication, experimental drug.
Use in renal disease patients
Canagliflozin, dapagliflozin or empagliflozin should not be initi-
ated in patients with an eGFR <60 mL/min/1.73 m2 and should be
discontinued at a GFR persistently <45 mL/min/1.73 m2.
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related to tubuloglomerular feedback inducing afferent arteriole
vasoconstriction, thus complementing efferent arteriole vasodi-
lation by RAS blockade and further lowering intraglomerular
pressure, glomerular hyperfiltration and albuminuria [37]. The
tubuloglomerular feedback would be triggered by increased so-
dium availability in the distal nephron, as SGLT2 inhibition pre-
vents both sodium and glucose reabsorption in proximal
tubules.
Additional mechanisms of action have been proposed for
the cardiovascular and nephroprotective effects that exceed
those of other antidiabetic drugs with a greater impact on glu-
cose control as summarized recently [37]. These may include
but are not limited to lowering body weight, blood pressure, uric
acid, plasma volume and proximal tubular cell glucotoxicity,
oxidative stress, inflammation and oxygen consumption and
increasing natriuresis, haemoglobin levels and insulin sensitiv-
ity [37].
WHAT IS ATRASENTAN?
Endothelin-1 is a vasoactive peptide with cytokine-like proper-
ties shown to contribute to the pathogenesis of DKD in preclini-
cal studies [46]. Atrasentan is a selective endothelin receptor
type A (ETA) antagonist initially studied for the potential treat-
ment of cancer [47]. However, clinical development for cancer
was discontinued. Early success with ETA antagonists in de-
creasing albuminuria in DKD patients was marred by volume
overload, which led to the termination of RCTs with avosentan
for nephroprotection due to an excess of heart failure episodes
[48]. The SONAR Phase 3 RCT explored nephroprotection by
atrasentan in DKD and incorporated an innovation to prior tri-
als: the exclusion of patients at risk of heart failure. This was
done in two sequential steps: exclusion of patients with base-
line brain natriuretic peptide (BNP) >200 pg/mL or a history of
heart failure or of severe peripheral oedema, followed by an en-
richment period that selected patients for albuminuria response
plus lack of substantial fluid retention (an increase in body-
weight 3 kg and a BNP increase to 300 pg/mL) once on atra-
sentan [2]. In our opinion, these sequential steps to improve
safety may severely compromise the external validity of the
results and their use in routine clinical practice.
WHAT WAS LEARNED FROM THE SONAR
TRIAL TESTING ATRASENTAN TO TREAT DKD?
SONAR randomized 2648 adults with T2DM, an eGFR 25–75 mL/
min/1.73 m2 and a UACR 300–5000 mg/g on RAS blockade to
atrasentan or placebo and followed them for a median of
2.2 years [2] (Figure 1). The trial was event-driven and was ter-
minated prematurely when it was predicted that the pre-speci-
fied number of events would not be reached. The primary
composite renal outcome of doubling of serum creatinine or
ESRD was reached in 6.0% of atrasentan and 7.9% of placebo
patients with an HR of 0.65 (95% CI 0.49–0.88; P¼ 0.0047)
(Figure 2B). The difference was also significant for doubling of
serum creatinine [HR 0.61 (95% CI 0.43–0.87)] but not for ESRD
[HR 0.73 (95% CI 0.53–1.01)], despite a greater number of ESRD
than doubling of serum creatinine events.
Atrasentan, used under the conditions of the trial, was found
to be safe but, at the same time, it did not provide a cardiovas-
cular advantage. There were no significant differences in a sec-
ondary cardiovascular composite endpoint (cardiovascular
death, non-fatal myocardial infarction or non-fatal stroke) or in
hospital admissions for heart failure [HR 1.33 (95% CI 0.85–2.07)]
or deaths (Figure 3B). Still, there were significantly more epi-
sodes of fluid retention (36.6% versus 32.3%, P¼ 0.022), but not
of cardiac failure (5.5% versus 3.9%, P¼ 0.064).
HOW WILL THIS NEW KNOWLEDGE IMPACT
CLINICAL PRACTICE? THE NEW ERA OF
SGLT2I/RAS BLOCKADE FOR DKD
The impact of CREDENCE is expected to be more immediate
than that of SONAR. In our view, CREDENCE sets the stage for
an indication of canagliflozin for the treatment of DKD as the
combination of canagliflozin and RAS blockade achieved a very
low residual renal risk (Figure 2C). This would result in a major
paradigm change from using SGLT2is to treat T2DM to using
them to treat DKD, independent from any antidiabetic effect.
Furthermore, it should expand the indication of canagliflozin to
patients with eGFR below the current limits of 60 mL/min/1.73
m2 for initiation and 45 mL/min/1.73 m2 for maintenance.
Indeed, since the drug was not stopped until patients initiated
RRT, there should be no limits for canagliflozin prescription
based on eGFR. It is likely that CREDENCE evidenced a nephro-
protective class effect, but regulatory indications for other
SGLT2is for DKD will likely await the results of RCTs with simi-
lar primary endpoints. This new knowledge will likely open the
door for testing SGLT2i/RAS blockade for nephroprotection in
T1DM as well as in other forms of CKD. The later will be ex-
plored by the EMPA-KIDNEY (The Study of Heart and Kidney
Protection With Empagliflozin; NCT03594110) and DAPA-CKD (A
Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes
and Cardiovascular Mortality in Patients With Chronic Kidney
Disease; NCT03036150) [49]. An improved understanding of
nephroprotective effects obtained from clinical studies may
also help advance the field of CKD therapy. In this regard, a re-
cent RCT disclosed evidence of proximal tubular cell protection
by dapagliflozin [50].
The impact of SONAR on the regulatory fate and eventual
clinical use of atrasentan is less clear. On the one hand, SONAR
has clearly demonstrated that atrasentan preserves renal func-
tion in addition to decreasing albuminuria. However, this was
shown against the old benchmark of RAS blockade, and the field
has shifted towards a new benchmark of RAS blockade plus
SGLT2i. Thus, even if atrasentan is approved for a DKD indica-
tion, its current role in clinical practice would be unclear. On the
other hand, the particular design of the SONAR trial, and espe-
cially the need for a first BNP determination at baseline and a
second measurement in the enrichment period, can represent a
serious hindrance to the widespread use of atrasentan in dia-
betic patients. In addition, nephroprotection afforded by atra-
sentan was not associated with cardiovascular benefit, even
after multiple baseline and early exclusions based on cardiovas-
cular safety. This again benchmarks negatively with current
drugs such as SGLT2is that provide both kidney and cardiovas-
cular benefit. However, there is the distinct possibility that the
combined nephroprotection afforded by atrasentan and SGLT2i
on top of RAS blockade further reduces the residual risk and
that additionally the combination offsets any potential deleteri-
ous effect of atrasentan on heart failure. Nevertheless, as attrac-
tive as this hypothesis might seem, it requires formal
assessment in new, specifically designed RCTs. In addition, al-
though T1DM was not explored in SONAR, T1DM patients may
be a niche for atrasentan, given the potential for ketoacidosis
with SGLT2is in these patients.
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